Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by Marshall Wace LLP

Marshall Wace LLP trimmed its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 70.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,382 shares of the company's stock after selling 96,624 shares during the period. Marshall Wace LLP owned about 0.08% of Enliven Therapeutics worth $931,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Barclays PLC raised its position in shares of Enliven Therapeutics by 14.8% in the fourth quarter. Barclays PLC now owns 64,563 shares of the company's stock valued at $1,453,000 after buying an additional 8,346 shares during the last quarter. Invesco Ltd. grew its position in shares of Enliven Therapeutics by 3.5% in the fourth quarter. Invesco Ltd. now owns 15,072 shares of the company's stock valued at $339,000 after purchasing an additional 508 shares during the period. FMR LLC increased its stake in Enliven Therapeutics by 3.2% in the fourth quarter. FMR LLC now owns 6,495,871 shares of the company's stock valued at $146,157,000 after purchasing an additional 199,692 shares during the last quarter. Federated Hermes Inc. acquired a new position in Enliven Therapeutics in the fourth quarter valued at $2,645,000. Finally, Wells Fargo & Company MN lifted its position in Enliven Therapeutics by 49.9% during the fourth quarter. Wells Fargo & Company MN now owns 16,666 shares of the company's stock worth $375,000 after buying an additional 5,548 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright upped their price objective on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the company a "buy" rating in a research note on Friday, March 21st.

Enliven Therapeutics Trading Down 2.1 %

ELVN traded down $0.43 during trading on Tuesday, hitting $19.97. 23,112 shares of the company's stock were exchanged, compared to its average volume of 258,829. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $30.03. The stock has a 50 day moving average price of $19.17 and a 200 day moving average price of $22.28. The firm has a market cap of $979.60 million, a P/E ratio of -10.51 and a beta of 1.07.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.07. The company had revenue of $0.03 million during the quarter. Analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, COO Anish Patel sold 6,667 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $21.93, for a total transaction of $146,207.31. Following the sale, the chief operating officer now directly owns 329,977 shares in the company, valued at $7,236,395.61. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Samuel Kintz sold 12,500 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $20.83, for a total value of $260,375.00. Following the completion of the transaction, the chief executive officer now directly owns 990,392 shares in the company, valued at approximately $20,629,865.36. The trade was a 1.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 77,111 shares of company stock valued at $1,539,266. 29.20% of the stock is currently owned by insiders.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.